The Fort Worth Press - MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

USD -
AED 3.672503
AFN 64.999811
ALL 82.324126
AMD 360.540277
ANG 1.790403
AOA 918.000169
ARS 1544.939993
AUD 1.47493
AWG 1.8
AZN 1.698924
BAM 1.769883
BBD 2.014669
BDT 124.715381
BGN 1.77347
BHD 0.378283
BIF 3011.021908
BMD 1
BND 1.291151
BOB 11.678099
BRL 5.666297
BSD 1.000231
BTN 94.44641
BWP 14.015512
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42537
CDF 2315.000184
CHF 0.837958
CLF 0.025469
CLP 1002.376741
CNY 6.67175
CNH 6.673395
COP 3319.97
CRC 449.312832
CUC 1
CUP 24.064952
CVE 100.149904
CZK 22.122964
DJF 178.554905
DKK 6.77912
DOP 60.996961
DZD 137.215041
EGP 53.460841
ERN 15
ETB 164.576405
EUR 0.906405
FJD 2.27435
FKP 0.756889
GBP 0.756398
GEL 2.590269
GGP 0.756889
GHS 11.724953
GIP 0.756889
GMD 74.000357
GNF 8883.748356
GTQ 7.646644
GYD 209.264655
HKD 7.84526
HNL 26.963306
HRK 6.831965
HTG 131.491813
HUF 330.867502
IDR 18235.4
ILS 3.216696
IMP 0.756889
INR 94.245498
IQD 1520.116116
IRR 1913737.498051
ISK 123.929951
JEP 0.756889
JMD 158.434254
JOD 0.709004
JPY 159.657496
KES 130.049851
KGS 87.435501
KHR 4080.00019
KMF 447.000297
KPW 900.00035
KRW 1335.484966
KWD 0.31147
KYD 0.835579
KZT 446.945163
LAK 22570.87132
LBP 89792.715562
LKR 333.505692
LRD 170.463102
LSL 16.951422
LTL 2.952741
LVL 0.60489
LYD 6.463464
MAD 9.936862
MDL 18.213816
MGA 4555.721867
MKD 55.830725
MMK 2100.274506
MNT 3605.662913
MOP 8.103688
MRU 40.552456
MUR 47.619801
MVR 15.400731
MWK 1738.739965
MXN 18.526497
MYR 4.086105
MZN 63.902977
NAD 16.951422
NGN 1343.570244
NIO 36.90298
NOK 10.16413
NPR 151.114437
NZD 1.808483
OMR 0.385095
PAB 1.000231
PEN 3.411802
PGK 4.575679
PHP 63.960117
PKR 277.274459
PLN 3.994115
PYG 6207.891986
QAR 3.64425
RON 4.851895
RSD 106.558993
RUB 82.765228
RWF 1483.467138
SAR 3.82571
SBD 8.097697
SCR 13.874904
SDG 601.490624
SEK 10.06572
SGD 1.287102
SHP 0.752984
SLE 23.050404
SLL 20969.503664
SOS 573.048487
SRD 37.490144
STD 20697.981008
STN 22.225246
SVC 8.773983
SYP 13002.000337
SZL 16.946523
THB 33.874985
TJS 9.249966
TMT 3.5
TND 3.008497
TOP 2.40776
TRY 50.346255
TTD 6.806368
TWD 32.891398
TZS 2655.145825
UAH 45.588969
UGX 4131.053487
UYU 40.541335
UZS 12057.876355
VES 912.87925
VND 25725.5
VUV 120.320092
WST 2.810586
XAF 594.562705
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.807139
XDR 0.707052
XOF 594.562705
XPF 108.324971
YER 236.550281
ZAR 16.93755
ZMK 9001.216069
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.080549
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief.

Text size:

"The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA," stated Erez Aminov, Chairman and CEO of MIRA. "By advancing two distinct formulations, we are positioning Ketamir-2 to address multiple pain conditions and broaden its potential applications. This strategic approach strengthens our presence in the pain management space and underscores our commitment to delivering innovative solutions while creating value for our shareholders."

Expanding Therapeutic Potential with Topical Ketamir-2

The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects. By offering localized relief, topical Ketamir-2 has the potential to transform the treatment landscape for neuropathic and inflammatory pain conditions, which currently lack effective long-term solutions.

Potential applications include:

  • Neuropathic Pain Conditions - Covers diabetic neuropathy, postherpetic neuralgia (shingles-related pain), chemotherapy-induced peripheral neuropathy (CIPN), and complex regional pain syndrome (CRPS)-all of which cause chronic nerve pain and significantly impact quality of life.

  • Inflammatory Pain Conditions - Includes osteoarthritis and rheumatoid arthritis, affecting millions of people worldwide and contributing to long-term disability and reduced mobility.

  • Nerve Compression & Musculoskeletal Pain - Addresses conditions like carpal tunnel syndrome, sciatica, and anterior cutaneous nerve entrapment syndrome (ACNES), which result in localized nerve pain due to compression, inflammation, or injury.

Addressing Limitations of Current Pain Treatments

Current treatment options for localized neuropathic and inflammatory pain-including NSAIDs, lidocaine patches, capsaicin creams, gabapentin, pregabalin, and opioids-offer limited relief and come with significant side effects:

  • NSAIDs & Over-the-Counter Topicals - Provide minimal relief for nerve pain and can cause skin irritation and gastrointestinal issues.

  • Anticonvulsants & Antidepressants (Gabapentin, Pregabalin, Duloxetine) - Frequently prescribed but associated with dizziness, sedation, and cognitive impairment.

  • Opioids - Highly addictive with severe dependency risks, making them unsuitable for long-term pain management.

"One of the biggest challenges in treating neuropathic pain is the lack of safe, effective, and targeted therapies," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Many current treatments either fail to provide adequate relief or come with serious side effects, limiting their long-term use. Ketamir-2's topical treatment has the potential to overcome these issues by delivering localized pain relief without the systemic side effects seen with oral medications. This could represent a significant advancement in neuropathic pain management."

Unlike existing treatments-such as NSAIDs, lidocaine patches, capsaicin creams, and systemic painkillers-topical Ketamir-2 aims to provide effective, long-lasting relief without the risks of systemic side effects, sedation, or opioid dependency. This innovative formulation builds on its unique mechanism of action and on research into topical ketamine, which has been used in compounded pain creams but lacks the bioavailability, consistency, and targeted action of Ketamir-2's novel design.

Advancing Clinical and Preclinical Programs

MIRA is actively advancing one clinical program and multiple preclinical programs, with significant milestones anticipated this year:

  • Phase 1 Clinical Trial Progressing Smoothly - The ongoing Phase 1 study for the Ketamir-2 oral treatment for neuropathic pain is advancing as planned, with full results anticipated later this year.

  • PTSD Studies Underway - Preclinical studies are investigating Ketamir-2's potential in treating PTSD, further expanding the drug's neuropsychiatric applications.

  • Phase 2a for Diabetic Neuropathy Expected to Begin by Year-End - Preparations are underway for a Phase 2a study in diabetic neuropathy patients, with first human efficacy data expected by Q1 2026.

  • Ongoing Animal Study for Topical Ketamir-2 in Inflammatory Pain - A preclinical study is currently assessing the efficacy of the new topical formulation in treating inflammatory pain, further expanding its potential applications as a topical agent for chronic pain conditions.

  • MIRA-55 for Memory Enhancement - Continued preclinical studies are evaluating MIRA-55's potential cognitive benefits, with results expected to support future clinical development.

Conclusion

The successful development of both an oral and topical formulation of Ketamir-2 represents a significant step in broadening MIRA's pain management pipeline. By pursuing multiple formulations, the Company is working to expand the potential applications of Ketamir-2 while strategically positioning itself in the pain therapeutics market. As MIRA advances toward key clinical milestones, this approach reflects its commitment to innovation and long-term growth.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: MIRA Pharmaceuticals



View the original press release on ACCESS Newswire

L.Holland--TFWP